Vasodilators, drugs that increase blood flow by direct or indirect action on the peripheral blood vessels, are widely advertised in medical journals and consume a considerable amount of annual drug dollar expenditures. The effects of vasodilator drugs are not restricted to areas of deficient blood supply, but are manifest throughout the peripheral vasculature. The facial cutaneous vasculature appears especially sensitive to these agents; flushing is reported as a side effect for nearly every vasodilator drug1-3(Table).
Flushing has long been assigned a role in the pathogenesis and exacerbations of stigmas of rosacea.4 Recently, I have seen several patients who had an exacerbation of both erythematous telangiectatic and papular components of rosacea developing with the initiation of vasodilator therapy. I am reporting here one such case.
Report of a Case
A 74-year-old man had had a 14-year history of erythema, telangiectasia, and papules on the nose and cheeks. He
Wilkin JK. Vasodilator Rosacea. Arch Dermatol. 1980;116(5):598. doi:10.1001/archderm.1980.01640290108028
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: